218 related articles for article (PubMed ID: 34583596)
21. Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors.
Porter NJ; Mahendran A; Breslow R; Christianson DW
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13459-13464. PubMed ID: 29203661
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors.
Senger J; Melesina J; Marek M; Romier C; Oehme I; Witt O; Sippl W; Jung M
J Med Chem; 2016 Feb; 59(4):1545-55. PubMed ID: 26653328
[TBL] [Abstract][Full Text] [Related]
23. Zinc binding groups for histone deacetylase inhibitors.
Zhang L; Zhang J; Jiang Q; Zhang L; Song W
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):714-721. PubMed ID: 29616828
[TBL] [Abstract][Full Text] [Related]
24. Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma.
Nepali K; Hsu TI; Hsieh CM; Lo WL; Lai MJ; Hsu KC; Lin TE; Chuang JY; Liou JP
Eur J Med Chem; 2021 May; 217():113338. PubMed ID: 33744690
[TBL] [Abstract][Full Text] [Related]
25. Isoform-selective HDAC1/6/8 inhibitors with an imidazo-ketopiperazine cap containing stereochemical diversity.
Lecointre B; Narozny R; Borrello MT; Senger J; Chakrabarti A; Jung M; Marek M; Romier C; Melesina J; Sippl W; Bischoff L; Ganesan A
Philos Trans R Soc Lond B Biol Sci; 2018 Jun; 373(1748):. PubMed ID: 29685969
[TBL] [Abstract][Full Text] [Related]
26. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
27. Methods for the expression, purification, and crystallization of histone deacetylase 6-inhibitor complexes.
Osko JD; Christianson DW
Methods Enzymol; 2019; 626():447-474. PubMed ID: 31606087
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological evaluation of selective histone deacetylase 6 inhibitors as multifunctional agents against Alzheimer's disease.
Wang XX; Xie F; Jia CC; Yan N; Zeng YL; Wu JD; Liu ZP
Eur J Med Chem; 2021 Dec; 225():113821. PubMed ID: 34517222
[TBL] [Abstract][Full Text] [Related]
29. Identification of novel 1,3-diaryl-1,2,4-triazole-capped histone deacetylase 6 inhibitors with potential anti-gastric cancer activity.
Zhang XH; Kang HQ; Tao YY; Li YH; Zhao JR; Ya-Gao ; Ma LY; Liu HM
Eur J Med Chem; 2021 Jun; 218():113392. PubMed ID: 33831778
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and evaluation of novel indirubin-based N-hydroxybenzamides, N-hydroxypropenamides and N-hydroxyheptanamides as histone deacetylase inhibitors and antitumor agents.
Anh DT; Hai PT; Dung DTM; Dung PTP; Huong LT; Park EJ; Jun HW; Kang JS; Kwon JH; Tung TT; Han SB; Nam NH
Bioorg Med Chem Lett; 2020 Nov; 30(22):127537. PubMed ID: 32916298
[TBL] [Abstract][Full Text] [Related]
31. Novel spiroindoline HDAC inhibitors: Synthesis, molecular modelling and biological studies.
Brindisi M; Senger J; Cavella C; Grillo A; Chemi G; Gemma S; Cucinella DM; Lamponi S; Sarno F; Iside C; Nebbioso A; Novellino E; Shaik TB; Romier C; Herp D; Jung M; Butini S; Campiani G; Altucci L; Brogi S
Eur J Med Chem; 2018 Sep; 157():127-138. PubMed ID: 30092367
[TBL] [Abstract][Full Text] [Related]
32. Novel 2, 5-diketopiperazine derivatives as potent selective histone deacetylase 6 inhibitors: Rational design, synthesis and antiproliferative activity.
Chen X; Chen X; Steimbach RR; Wu T; Li H; Dan W; Shi P; Cao C; Li D; Miller AK; Qiu Z; Gao J; Zhu Y
Eur J Med Chem; 2020 Feb; 187():111950. PubMed ID: 31865013
[TBL] [Abstract][Full Text] [Related]
33. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis and biological evaluation of dual mTOR/HDAC6 inhibitors in MDA-MB-231 cells.
Yao D; Jiang J; Zhang H; Huang Y; Huang J; Wang J
Bioorg Med Chem Lett; 2021 Sep; 47():128204. PubMed ID: 34139324
[TBL] [Abstract][Full Text] [Related]
35. Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors.
Tavares MT; de Almeida LC; Kronenberger T; Monteiro Ferreira G; Fujii de Divitiis T; Franco Zannini Junqueira Toledo M; Mariko Aymoto Hassimotto N; Agostinho Machado-Neto J; Veras Costa-Lotufo L; Parise-Filho R
Bioorg Med Chem; 2021 Apr; 35():116085. PubMed ID: 33668008
[TBL] [Abstract][Full Text] [Related]
36. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
37. Exploring new histone deacetylase 6 inhibitors and their effects on reversing the α-tubulin deacetylation and cell morphology changes caused by methamphetamine.
Gupta SK; Ali KH; Lee S; Seo YH
Arch Pharm Res; 2023 Oct; 46(9-10):795-807. PubMed ID: 37777709
[TBL] [Abstract][Full Text] [Related]
38. Exploring Structural Determinants of Inhibitor Affinity and Selectivity in Complexes with Histone Deacetylase 6.
Osko JD; Porter NJ; Narayana Reddy PA; Xiao YC; Rokka J; Jung M; Hooker JM; Salvino JM; Christianson DW
J Med Chem; 2020 Jan; 63(1):295-308. PubMed ID: 31793776
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and structure-activity relationship of thiol-based histone deacetylase 6 inhibitors.
Guo Z; Zhang Y; Bao Y; Huang Z; Gu X; Wang G; Li J
Chem Biol Drug Des; 2022 Jul; 100(1):90-107. PubMed ID: 35404520
[TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.
Mou Z; Gao J; Miao H; Zhang L; Su L; Wang B; Luan Y
Biosci Trends; 2019 Jul; 13(3):267-272. PubMed ID: 31155552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
